Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

International Assets Investment Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 98 ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

"The initial presentation typically includes dementia and neurological symptoms such as ataxia, myoclonus, and gait abnormalities as well as behavioral changes," Cetin and co-authors wrote. Sporadic ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...